Stefanie Mortimer
Guardant (United States) · 103 works · 4,142 citations · h-index 22
Top works
- Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA
- A Fast-Acting Reagent for Accurate Analysis of RNA Secondary and Tertiary Structure by SHAPE Chemistry
- Multiplexed RNA structure characterization with selective 2′-hydroxyl acylation analyzed by primer extension sequencing (SHAPE-Seq)
- Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies
- The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients
- Insights into RNA structure and function from genome-wide studies
- Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients
- Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non–small cell lung cancer: Analysis of over 8000 cases
- Modeling and automation of sequencing-based characterization of RNA structure
- Time-resolved RNA SHAPE chemistry: quantitative RNA structure analysis in one-second snapshots and at single-nucleotide resolution
- Time-Resolved RNA SHAPE Chemistry
- Influence of nucleotide identity on ribose 2′-hydroxyl reactivity in RNA
- SHAPE–Seq: High‐Throughput RNA Structure Analysis
- Crystal Structure of the HCV IRES Central Domain Reveals Strategy for Start-Codon Positioning
- Two RNA-binding motifs in eIF3 direct HCV IRES-dependent translation
- Somatic genomic landscape of over 15,000 patients with advanced-stage cancer from clinical next-generation sequencing analysis of circulating tumor DNA.
- Slow Conformational Dynamics at C2′-endo Nucleotides in RNA
- Unconventional miR-122 binding stabilizes the HCV genome by forming a trimolecular RNA structure
- Somatic genomic landscape of over 15,000 patients with advanced-stage cancer from clinical next-generation sequencing analysis of circulating tumor DNA.
- Circulating tumor DNA (ctDNA) utilizing a high-sensitivity panel to detect minimal residual disease post liver hepatectomy and predict disease recurrence.